Estrogen receptor a (ERa) is a ligand-activated transcription factor that regulates expression of estrogen-responsive genes. Upon binding of the ligand-occupied ERa to estrogen response elements (EREs) in DNA, the receptor interacts with a variety of coregulatory proteins to modulate transcription of target genes. We have isolated and identified a number of proteins associated with the DNA-bound ERa. One of these proteins, Rho guanosine diphosphate (GDP) dissociation inhibitor a (RhoGDIa), is a negative regulator of the Rho family of GTP-binding proteins. In this study, we demonstrate that endogenously expressed RhoGDIa is present in the nucleus as well as the cytoplasm of MCF-7 breast cancer cells, and that RhoGDIa binds directly to ERa, alters the ERa-ERE interaction, and influences the ability of ERa to regulate transcription of a heterologous estrogen-responsive reporter plasmid in transient transfection assays as well as endogenous, estrogen-responsive genes in MCF-7 cells. Our studies suggest that, in addition to the activity of RhoGDIa in the cytoplasm, it also influences ERa signaling in the nucleus. E 2 -treated sample in the presence of control siRNA as determined by ANOVA (P%0 . 05). (B)
Introduction
Individual cells in multicellular organisms rely on a variety of signals from their surrounding environment to survive and function effectively. Neighboring and more distant cells produce a wide range of ligands including lipophilic hormones, peptides, and neurotransmitters that control various cellular functions ranging from metabolism, cell division, and differentiation to communication among cells from the same or different tissues. Once sensed by a cell, these ligands can initiate a cascade of intracellular events that oftentimes concludes with transcription factor activation and modulation of target gene expression. The receptors targeted by ligands can be intracellular such as steroid receptors or embedded in the cell membrane such as ligand-gated ion channels, receptor tyrosine kinase family members, or G protein-coupled receptors.
Rho GTP-binding proteins (RhoGTPases) are members of the Ras superfamily of GTP-binding proteins and are considered key players in the intracellular transmission of signals initiated by cellsurface receptors. RhoGTPases act as molecular switches cycling between an active, GTP-bound form, which is anchored to the cell membrane, and an inactive, GDP-bound form, which is present in the cytoplasm (Koch et al. 1997) . When bound to GTP, RhoGTPases interact with downstream effector proteins and foster signal propagation. Once GTP is hydrolyzed, RhoGTPase activity ceases and signal transduction is halted. Proteins that regulate the activity of these molecular switches include GTPase-activating proteins (GAPs), which enhance the rate of GTP hydrolysis, GDP dissociation inhibitors (GDIs), which inhibit the release of GDP from the GTPase, and GDP exchange factors (GEFs), which replace GTPase-bound GDP with GTP. While GAPs and GDIs are negative regulators, GEFs are positive regulators of GTPase activity (Hart et al. 1992) .
In addition to the signals initiated at the plasma membrane and propagated through the cytoplasm, some ligands, mainly lipophilic hormones, elicit their effects by targeting nuclear receptor superfamily members. In their classical mode of action, ligandoccupied nuclear receptors undergo a conformational change and interact with their cognate response elements in DNA to fulfill their function as transcription factors that regulate the expression of target genes. Through binding to specific nuclear receptors, lipophilic hormones regulate a variety of physiological processes. In addition to the traditional mode of nuclear receptor transactivation, there is accumulating evidence that receptors on the cell surface initiate signals that alter nuclear receptor activity. For example, epidermal growth factor (Kato et al. 1995 , Bunone 1996 , transforming growth factor a (Ignar- Trowbridge et al. 1993) , and insulin-like growth factor-I (Ma et al. 1994 ) are able to alter the capacity of nuclear receptors to activate gene expression. This nonclassical mode of nuclear receptor regulation can be hormone independent or hormone dependent and provides a link between various cues received by receptors on the cell surface and the activity of receptors in the nucleus.
Our laboratory has been interested in identifying proteins that influence estrogen-responsive gene expression. Using agarose gel mobility shift assays and mass spectrometry analysis, we identified novel HeLa nuclear proteins associated with the DNA-bound estrogen receptor a (ERa; Schultz-Norton et al. 2007) . One of these ERa-associated proteins was the 28 kDa protein Rho GDP dissociation inhibitor a (RhoGDIa), which was originally characterized as a negative regulator of the RhoGTPase family members RhoA, Rac1, and Cdc42 (Fukumoto et al. 1990 , Leonard et al. 1992 , Masuda et al. 1994 , Koch et al. 1997 , Olofsson 1999 . Although the ability of RhoGDIa to enhance transcription of an estrogen response element (ERE)-containing reporter plasmid has been reported previously, it was thought that this enhanced activity was due to the cytoplasmic actions of RhoGDIa (Su et al. 2001 (Su et al. , 2002 . Because we found RhoGDIa associated with the DNA-bound ERa, we investigated the localization of endogenously expressed RhoGDIa in MCF-7 breast cancer cells and characterized the ability of this protein to interact with ERa and influence the expression of estrogen-responsive genes.
Materials and Methods

Isolation of RhoGDIa
RhoGDIa was isolated with the ERE-bound ERa using HeLa nuclear extracts, purified ER, ERE-containing oligos, and agarose gel fractionation (Schultz-Norton et al. 2007) . Five unique peptides (SIQEQELDKDDESLR, VAV-SADPNVPNVVVTGLTLVCSSAPGPLELDLTGDLESFKK, IDKTDYMVGSYGPR, FTDDDKTDHLSWEWNLTIK, and AEEYEFLTPVEEAPK), which exclusively map to RhoG-DIa, were identified by mass spectrometry analysis as described (Loven et al. 2003) .
Western blots
Nuclear and cytosolic extracts were prepared from MCF-7 and MDA-MB-231 breast cancer cells and U2 osteosarcoma (U2OS) cells as previously described (Wood et al. 2001) . Ten micrograms of each extract were separated on a 15% SDS polyacrylamide gel and subjected to western analysis with an antibody directed against RhoGDIa, ERa, or lamin A/C (sc-360, sc-8002 and sc-20681 respectively, Santa Cruz Biotechnologies, Santa Cruz, CA, USA). The blots were then developed using a horseradish peroxidase-coupled secondary antibodies and a chemiluminescent detection system. The data included are representative of five different experiments.
Subcloning, expression, and purification of histagged RhoGDIa protein for gel shift assays A BamH1/EcoRI fragment of human RhoGDIa from pGST-GDI, kindly provided by M Garabedian (New York University, School of Medicine, New York), was subcloned into a dual-tagged (His and T7) pET-28a (C) vector (Novagen, La Jolla, CA, USA) for the expression of RhoGDIa protein. The plasmid was purified and used to transform Escherichia coli BL21-CodonPlus (DE3)-RIL competent cells (Stratagene, La Jolla, CA, USA) which were induced with 1 mM IPTG at 37 8C for 4 h, chilled on ice for 5 min, and pelleted at 4700 g for 10 min at 4 8C. Ni-NTA lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, and 10 mM imidazole) was added to the cell pellet and the lysate obtained was sonicated on ice and centrifuged at 142 000 g for 30 min at 4 8C. The supernatant was diluted with one-half volume of Ni-NTA lysis buffer and incubated with Ni-NTA agarose beads (Qiagen) with rotation for 1 h at 4 8C. The beads were washed thrice with Ni-NTA wash buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, and 0 . 5% Triton X-100).
His-RhoGDIa was eluted with Ni-NTA elution buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, and 250 mM imidazole). Protein purity was monitored on Coomassiestained gels. Protein concentration was determined using the Bio-Rad protein assay (Bio-Rad) using BSA as a standard.
Pull-down assay using purified proteins His, T7-tagged RhoGDIa was expressed and purified as described above using Ni-NTA. The purified protein was then immobilized on T7-Tag antibody agarose beads from T7-Tag Affinity purification kit (Novagen) according to the manufacturer's recommendation. Baculovirus expressed and purified ERa was incubated with immobilized RhoGDIa at 4 8C for 1 h without or with 10 nM 17b-estradiol (E 2 ). The beads were washed thrice with buffer provided in the purification kit and proteins were eluted with 2X SDS sample buffer (125 mM Tris pH 6 . 8, 4% SDS, 20% glycerol, 10% b-mercaptoethanol). Lysates from E. coli cells transformed with parental plasmid without RhoGDIa were purified in parallel. Western analysis was performed using a monoclonal antibody against ERa (sc-8002, Santa Cruz Biotechnologies). Similar results were obtained in three independent experiments.
Coimmunoprecipitation assays MCF-7 cells were grown to 80% confluency in 10 cm dishes in phenol red-free minimum essential medium (MEM, Invitrogen) containing 5% charcoal-dextrantreated calf serum (CDCS) then maintained for 6 h in phenol red-free MEM containing 0 . 4% fetal calf serum (FCS) before being treated for 24 h with 10 nM E 2 or ethanol. The cells were washed thrice in cold 1X PBS and lysed in 500 ml ice-cold lysis buffer (20 mM Tris pH 7 . 4, 10 mM EDTA, 100 mM NaCl, 0 . 5% IGEPAL, 1 mM Na 3 VO 4 , 50 mM NaF, and 1X protease inhibitor cocktail (PIC, Sigma)). Equal amounts of the cell lysate were incubated with 1 mg of fluorescein-specific antibody (University of Illinois, Immunological Resource Center, Urbana, IL, USA) or RhoGDIa-specific antibody (sc-360, Santa Cruz Biotechnology) for 12 h at 4 8C under gentle agitation. Forty microlitres of 50% protein A sepharose slurry was added and the samples were rotated for 1 h at 4 8C. The samples were then pelleted, washed thrice with wash buffer (20 mM Tris pH 7 . 4, 10 mM EDTA, 100 mM NaCl, 0 . 1% IGEPAL, 1 mM Na 3 VO 4 , 50 mM NaF, and 1X PIC), and eluted with 2X SDS sample buffer for SDS-PAGE analysis followed by immunoblotting using an antibody against ERa (sc-8002, Santa Cruz Biotechnologies). The data shown are representative of four independent experiments.
Transient transfections
U2OS cells were maintained in phenol red-containing MEM with 10% FCS. Two days before plating, cells were transferred to phenol red-containing MEM supplemented with 5% CDCS. After 24 h, cells were transferred to phenol red-free MEM containing 5% CDCS. Cells were then seeded in 24 well plates at 2 . 5!10 4 cells/well and transfected with 20 ng CMV5-hERa (Reese & Katzenellenbogen 1991) , 10 ng TK-Renilla (Promega), and 1 mg of a luciferase reporter vector containing two copies of the consensus ERE (2ERE-TK-Luciferase, kindly provided by B Katzenellenbogen, University of Illinois, Urbana, IL, USA) without or with 10-1000 ng of a RhoGDIa expression vector (pCDNA-RhoGDIa, kindly provided by M Garabedian, New York University, School of Medicine, New York). A parental expression vector lacking the RhoGDIa sequence was used to maintain a constant amount of DNA in each well. Cells were transfected using lipofectin (Invitrogen) for 6 h, after which they were treated with ethanol vehicle or 10 nM E 2 for 24 h. Luciferase activity was quantitated using the Dual Luciferase Assay kit (Promega). The data shown were derived from three independent experiments. Significant differences in luciferase activity were calculated by ANOVA using SAS.
Gene silencing with RNA interference MCF-7 cells were maintained in phenol red-containing MEM supplemented with 5% calf serum and placed on phenol red-free MEM with 5% CDCS 24 h prior to transfection. Cells were then seeded at 4!10 5 cells/well in 12-well plates 24 h prior to transfection using phenol red-free MEM with 5% CDCS without antibiotics and transfected with 50 pmol of control (renilla luciferase) or RhoGDIa-specific siRNA oligos (4630 or 46085 respectively, Ambion, Austin, TX, USA) in the absence of antibiotics using siLenFect (Bio-Rad) for 24 h. Media was replaced with phenol red-free, antibiotic-free MEM with 5% CDCS for an additional 24 h without or with 10 nM E 2 . Cells were then lysed in lysis buffer and western blot analysis was performed using antibodies to RhoGDIa, ERa, GAPDH (sc-360, sc-8002, and sc-20357 respectively, Santa Cruz Biotechnology), or PR (RM-9102, LabVision, Fremont, CA, USA). RNA was harvested using Trizol (Invitrogen) and processed according to the manufacturer's directions. cDNA was synthesized using the Reverse Transcription System (Promega). Real-time PCR was performed using iQ SYBR Green Supermix and the iCycler PCR thermocycler (Bio-Rad) according to the manufacturer's directions. Primer sets for: GAPDH (5 0 -CGC TCT CTG CTC CTC CTG-3 0 and 5 0 -TCC GTT GAC TCC GAC CTT-3 0 ), RhoGDIa (5 0 -ACC CAG CCA GGA ACA AAC-3 0 and 5 0 -GCA GAC ACA ACA CGA AGA C-3 0 ), ERa (5 0 -TGC CCT ACT ACC TGG AGA AC-3 0 and 5 0 -CCA TAG CCA TAC TTC CCT TGT C-3 0 ), PR (5 0 -GTG CCT ATC CTG CCT CTC AAT C-3 0 and 5 0 -CCC GCC GTC GTA ACT TTC G-3 0 ), and pS2 (5 0 -GCT GTT TCG ACG ACA CCG TT-3 0 and 5 0 -TTC TGG AGG GAC GTC GAT G-3 0 ) were utilized. Standard curves were derived using serial dilutions of cDNA equivalent to 0 . 025, 0 . 25, 2 . 5, and 25 ng input RNA and were run in duplicate for each primer set during each experiment. The relative nanograms of RNA were determined from the standard curve. The average of three replicates from one experiment is shown which is representative of four independent experiments. Significant changes in RNA levels due to specific siRNA or hormone exposure were calculated by ANOVA using SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Gel mobility shift assays
Gel mobility shift assays were carried out as described previously with the following modifications. 32 P-labeled, 50 bp ERE-containing oligos were incubated for 10 min at 4 8C in binding reaction buffer (15 mM Tris, pH 7 . 9, 20 mM KCl, 0 . 2 mM EDTA, 10% glycerol, 50 ng/ml poly dI/dC, 4 mM dithiothreitol, and 50 nM E 2 ) with a constant amount (50 fmoles) of baculovirus expressed, purified ERa, and increasing amounts of purified RhoGDIa. BSA and Ni-NTA elution buffer were added as needed to maintain constant protein and salt concentrations. For antibody supershift experiments, ERa-and RhoGDIa-specific antibodies (sc-8002 and sc-360 respectively, Santa Cruz Biotechnology) were added to the binding reaction mixture and incubated for an additional 10 min at room temperature. Samples were loaded onto a 6% nondenaturing polyacrylamide gel and fractionated using low ionic strength buffer as described previously (Chodosh & Buratowski 1989) . Radioactive bands were visualized by autoradiography. Three independent experiments were performed.
Fluorescence microscopy MCF-7 cells were grown on poly-L-lysine-treated cover slips in phenol red-free MEM medium containing 5% CDCS and exposed to 10 nM E 2 or ethanol vehicle for the indicated times. Cells were fixed in 1X PBS containing 4% formaldehyde and 4% sucrose for 10 min and permeabilized in 1X PBS with 0 . 2% Triton X-100 for 20 min. Blocking was performed in blocking buffer (2% BSA, 2% FBS, 0 . 1% Tween-20, and 0 . 02% NaN 3 in 1X PBS) for 45 min at room temperature. When digitonin was used, the cells were first washed with transport buffer (20 mM HEPES pH 7 . 4, 110 mM potassium acetate, 2 mM magnesium acetate, and 0 . 5 mM EGTA), then treated with 0 . 005% (wt/vol) digitonin in transport buffer for 6 min at 4 8C. Cover slips were washed thrice in transport buffer and incubated for 20 min at room temperature before being fixed, permeabilized, and blocked as indicated above. Cells were incubated with rabbit polyclonal antibody against RhoGDIa (sc-360, Santa Cruz Biotechnology) alone or combined with either a mouse monoclonal antibody that recognizes a related family of NPC proteins (MMS-120P, Covance, Berkely, CA, USA) or a mouse monoclonal antibody that recognizes the nucleolar protein fibrillarin (Abcam Ab18380, Cambridge, MA, USA) in blocking buffer for 1 h at room temperature in a humidified box. Cells were washed thrice in 1X PBS with 0 . 1% Tween-20 and incubated with a fluorescein conjugated, donkey antirabbit secondary antibody, alone or combined with donkey anti-mouse, Texas Red conjugated, secondary antibody (Jackson Immunoresearch, West Grove, PA, USA) for 1 h at room temperature in a humidified box. The nuclei were counterstained with 4 0 -6-diamidino-2phenylindole and mounted with Vectashield mounting medium (Vector Labortories Inc., Burlingame, CA, USA). Digital images were captured by a charge-coupled device camera (Hamamatsu ORCA, Bridgewater, NJ, USA) mounted on a Nikon Microphot-SA microscope (Melville, NY, USA) using Openlab software 2.0.6 (Improvision I, Lexington, MA, USA). Montages of digital images were assembled in Adobe Photoshop 7.0.
Results
RhoGDIa has been described as a ubiquitously expressed protein, which is found primarily in the cytoplasm of cells (Koch et al. 1997 ). Thus, we were surprised when we identified endogenously expressed RhoGDIa from HeLa nuclear extracts as a component of a large multiprotein complex associated with the DNA-bound ERa (Schultz-Norton et al. 2007) .
RhoGDIa is present in the cytoplasm and the nucleus
We undertook a series of experiments to monitor the localization of endogenously expressed RhoGDIa in cultured cell lines that have been used to study estrogen-responsive gene expression. As expected, RhoGDIa was detected in the cytosolic fractions (C) of ERa-positive MCF-7 breast cancer cells in the absence and presence of 10 nM E 2 , ERa-negative MDA-MB-231 breast cancer cells, and U2 osteosarcoma (U2OS) cells using western analysis (Fig. 1, lanes 2, 4, 6, and 8) . RhoGDIa was also observed in the nuclear fractions (N) of MCF-7 and U2OS cells (Fig. 1, lanes 1, 3, and 7) . Although RhoGDIa was not visible in MDA-MD-231 nuclear extracts in the data shown, we were able to detect RhoGDIa in MDA-MB-231 nuclear extracts using higher antibody concentrations (data not shown). As expected, ERa was present only in MCF-7 cells. Lamin A/C was used as a loading control to demonstrate that similar amounts of protein were loaded.
While our western analysis had demonstrated that RhoGDIa was present in MCF-7 and U2OS nuclear extracts, it seemed possible that homogenization of these cells could have resulted in the redistribution of some proteins. To examine the localization of endogenously expressed RhoGDIa in its native cell environment, immunocytochemistry (ICC) was performed in MCF-7 cells using a RhoGDIa-specific antibody. (N, lanes 1, 3, 5, 7) and cytosolic (C, lanes 2, 4, 6, 8) extracts (10 mg) from MCF-7, MDA-MB-231, and U2OS cells were tested for the presence of RhoGDIa and ERa using western analysis. Lamin A/C was used as a loading control.
As anticipated, RhoGDIa was found predominantly in the cytoplasm, but was also present in the nucleus ( Fig. 2A) . The localization of RhoGDIa was largely unaffected when MCF-7 cells were treated with ethanol vehicle or 10 nM E 2 for 20 min or 24 h. No staining was observed when primary antibody was omitted or when primary antibody was preincubated with a tenfold excess of bacterially expressed, purified RhoGDIa (data not shown).
To confirm that RhoGDIa was present in MCF-7 nuclei, cells were treated with digitonin for 6 min to permeabilize the plasma membrane but not the nuclear envelope, so that soluble proteins such as RhoGDIa could diffuse out of the cytoplasm. The boundary of the nuclear compartment was defined by an antibody that recognizes a related family of nuclear pore complex (NPC) proteins (Fig. 2B ). Although no RhoGDIa was detected in the cytoplasm after digitonin treatment, it was present in the nuclei and appeared to be more concentrated in the nucleoli in the merged RhoGDIa and NPC images. The presence of RhoGDIa in the nucleoli was confirmed by its colocalization with the nucleolar protein fibrillarin in the merged images (Fig. 2C ).
RhoGDIa expression in MCF-7 cells is not affected by E 2 treatment
To assess whether exposure of MCF-7 cells to E 2 affected the level of RhoGDIa, cells were treated with ethanol vehicle or 10 nM E 2 for 0 . 3, 2, 24, 48, or 72 h and whole cell extracts were subjected to western analysis. No detectable changes in RhoGDIa protein levels were observed with any of the E 2 treatments examined (Fig. 3) . In contrast, ERa levels were decreased after 24 h and remained low as previously reported (Petz et al. 2004b) . GAPDH, which was used as a loading control, was unaffected by hormone treatment.
RhoGDIa enhances estrogen-mediated transactivation in U2OS cells
Since RhoGDIa was originally identified in a complex with the ERE-bound ERa (Schultz-Norton et al. 2007) and we had detected endogenously expressed Rho-GDIa in MCF-7 nuclei, we determined whether RhoGDIa could influence ERa-mediated transactivation. Transient transfections were carried out in U2OS cells using an ERa expression vector, a luciferase reporter plasmid containing two copies of the consensus ERE, and a renilla reporter plasmid, which was used as an internal control. As increasing amounts of a RhoGDIa expression vector were included, a dosedependent increase in E 2 -mediated transactivation was observed (Fig. 4) . These findings are in agreement with previous transfection experiments carried out in U2OS cells (Su et al. 2001) .
RhoGDIa alters endogenous expression of estrogenresponsive genes in MCF-7 cells
Our transient transfection studies indicated that overexpression of RhoGDIa increased ERa-mediated transactivation of a reporter gene containing a simple promoter and two tandem EREs. In order to study the effect of endogenously expressed RhoGDIa on transcription of native estrogen-responsive genes, RhoGDIa expression was knocked down in MCF-7 cells using small interfering RNA (siRNA) directed against exon 6 of RhoGDIa. In addition siRNA directed against renilla luciferase was used as a control. RhoGDIa mRNA levels were reduced when RhoGDIa-specific, but not control, siRNA was used regardless of hormone exposure (Fig. 5A ).When control siRNA was used, the levels of PR and pS2 mRNA were increased in the presence of E 2 and the level of ERa mRNA was decreased. These findings are consistent with previous reports on the effects of E 2 on PR and pS2 gene expression in MCF-7 cells (Nardulli et al. 1988 , Kim et al. 2000 . When RhoGDIa expression was decreased, there was an increase in the level of PR mRNA and a decrease in the level of pS2 mRNA in the presence of E 2 when compared with the control siRNA. Interestingly, ERa mRNA levels were substantially increased in the absence of E 2 when RhoGDIa was knocked down. GAPDH, which was used as an internal control, was unaffected by control or RhoGDIa siRNA. Taken together, these data demonstrate that RhoGDIa differentially influences the expression of endogenous, estrogen-responsive genes in MCF-7 cells. We also monitored the effect of knocking down RhoGDIa on RhoGDIa, ERa, and PR protein levels using western blot analysis. RhoGDIa levels were dramatically reduced when siRNA targeting RhoGDIa was used (Fig. 5B, compare lanes 1 and 2 with lanes  3 and 4) indicating that the RhoGDIa siRNA was effective in decreasing the levels of RhoGDIa mRNA and protein. When control siRNA was used, the level of ERa protein was decreased and the level of PR protein was increased in the presence of E 2 (lanes 1 and 2) as previously reported (Petz et al. 2004b) . When RhoGDIa-specific siRNA was used, ERa protein levels were increased in the absence of hormone (compare lanes 1 and 3) and PR protein levels were increased in the presence of E 2 (compare lanes 2 and 4). These findings are consistent with our RNA analysis. The level of GAPDH, which was used as an internal control, was unaffected by RhoGDIa expression.
RhoGDIa and ERa interact
To this point we had shown that RhoGDIa was present in the nuclei of MCF-7 cells and that altering RhoGDIa expression influenced estrogen-responsive gene expression. However, the mechanism by which Rho-GDIa might influence ERa-mediated transactivation remained unclear. It has been hypothesized that RhoGDIa might alter estrogen responsiveness through cytoplasmic RhoGDIa signaling (Su et al. 2002) . However, the presence of RhoGDIa and ERa in the nucleus of MCF-7 cells and the association of RhoGDIa with the DNA-bound ERa in our agarose gel shift assays suggested that RhoGDIa might interact with ERa and influence its activity. Thus, coimmunoprecipitation experiments were carried out to determine whether endogenously expressed RhoGDIa and ERa interacted in MCF-7 cells. As seen in Fig. 6A , ERa was associated with RhoGDIa in MCF-7 cells in the absence and presence of E 2 when an antibody against RhoGDIa (lanes 5 and 6), but not when a control antibody directed against fluorescein (lanes 3 and 4) , was used.
To determine whether the receptor and RhoGDIa could interact directly, RhoGDIa was expressed with dual His and T7-tags and passed through a Ni-NTA column to eliminate background before being immobilized on T7-tag beads. The immobilized protein was then incubated with baculovirus-expressed, purified ERa. As seen in Fig. 6B , RhoGDIa and ERa interacted directly in the absence and in the presence of E 2 (lanes 4 and 5). Control lanes containing lysate from bacteria, which had been transformed with the parent plasmid instead of RhoGDIa plasmid, failed to interact with ERa (lanes 2 and 3) .
RhoGDIa enhances the ERa-ERE interaction
Since ERa interacted directly with RhoGDIa, it seemed possible that this interaction might affect the ability of the receptor to bind to its cognate binding site, the ERE. Therefore, gel mobility shift assays were performed using constant amounts of purified ERa and 32 P-labeled, ERE-containing oligos. As increasing amounts of the purified His-tagged RhoGDIa were added, a slight decrease in the intensity of the band corresponding to ERa-ERE binary complex (C1) and an increase in the intensity of another, lower mobility Figure 5 Effect of RhoGDIa on the expression of endogenous, estrogen-responsive genes. MCF-7 cells were transfected with control or RhoGDIa-specific siRNA for 24 h and then treated with ethanol (open bars) or 10 nM E 2 (solid bars) for 24 h. (A) RNA was harvested, cDNA was synthesized, and quantitative RT-PCR analysis was performed using primers specific to RhoGDIa, PR, pS2, ERa, and GAPDH transcripts. Data are reported as the mean of triplicatesGS.E.M. and is representative of four independent experiments. Some error bars are too small to be visible. An asterisk indicates that the mRNA level detected in the presence of RhoGDIa siRNA was significantly different from the corresponding ethanol or band (C2) was observed (Fig. 7A, lanes 2-5) . As anticipated, the ERa-specific antibody supershifted both C1 and C2 (lane 6) demonstrating that ERa was present in both complexes. Curiously, the RhoGDIa antibody not only supershifted C2, which presumably contained the trimeric RhoGDIa-ERa-ERE complex (lane 7), but also caused the disappearance of C1, which contained the ERa-ERE complex. These findings suggest that the RhoGDIa-specific antibody fosters the formation of the trimeric RhoGDIa-Era-ERE complex and the depletion of the ERa-ERE complex. The ability of an antibody to stabilize the ERa-ERE complex has been reported previously and was attributed to the ability of the antibody to enhance receptor dimerization (Fawell et al. 1990) . It seems possible that the RhoGDIa antibody could likewise stabilize the association of RhoGDIa and ERa with the ERE-containing DNA. When RhoGDIa was incubated with ERE-containing oligos in the absence of ERa, no complex was observed (lane 8) demonstrating that the formation of the trimeric complex requires the receptor. The ability of the RhoGDIa antibody to supershift the trimeric complex required the presence of RhoGDIa protein as demonstrated by the inability of this antibody to supershift the ERa-ERE complex (Fig. 7B, lane 4) .
Discussion
We identified RhoGDIa in a large multiprotein complex associated with the DNA-bound ERa and characterized the ability of this protein to function as a regulator of ERa activity. We have shown that RhoGDIa not only increases ERa transcriptional activity in transient transfection assays but also differentially influences the expression of endogenous estrogenresponsive genes in MCF-7 cells. Our studies suggest that RhoGDIa collaborates with other regulatory proteins to modify the expression of ERa target genes.
We were initially surprised to find RhoGDIa among the proteins isolated in the protein-ERa-DNA complex, since it has typically been referred to as a cytoplasmic protein (Fukumoto et al. 1990 ) and we had utilized HeLa nuclear extracts to form our ERacontaining multiprotein complexes. However, western blot analysis and ICC assays confirmed the presence of RhoGDIa in the nuclei of MCF-7 cells. A careful examination of RhoGDIa amino acid sequence failed to identify any nuclear localization signal, suggesting that another protein may assist in the shuttling of RhoGDIa between the cytoplasm and the nucleus. It seems plausible that cdc42 isoform1, a RhoGTPase family member with a polybasic region in its C-terminal end that can function as a nuclear localization signal (Lanning et al. 2003 , Williams 2003 , might perform this function since we identified both isoforms 1 and 2 of cdc42 in our agarose gel purification experiments as ERa-associated proteins (Schultz-Norton et al. 2007) . Alternatively, RhoGDIa could be accompanied by a protein such as 14-3-3, which binds and helps to redistribute an array of signaling proteins (Fu et al. 2000 , Kino et al. 2003 , Diviani et al. 2004 . It should also be noted that the 28 kDa RhoGDIa is theoretically small enough to traverse the nuclear pores unaccompanied.
The concentration of RhoGDIa in the nucleolus was unexpected since this nuclear compartment has typically been viewed as the site of rRNA synthesis and ribosome assembly. However, there is accumulating evidence to suggest that nucleolar proteins play a dynamic role in regulating a number of cellular processes including cell cycle progression, cell proliferation, and regulation of gene expression (Weber et al. 1999 , Cerutti & Simanis 2000 . It has been suggested that localization of cdc14 in the nucleolus may help to ensure that it is sequestered from its cytoplasmic and nuclear substrates (Bachant & Elledge 1999) . Likewise, the localization of RhoGDIa in the nucleolus may help to simultaneously sequester RhoGDIa from cytoplasmic GTPases and from ERa and at the same time serve as a storage depot to maintain a pool of nuclear RhoGDIa protein that could interact with ERa and influence gene expression. The ability of RhoGDIa to alter ERa activity was previously reported by Garabedian and coworkers (Su et al. 2001) , who showed that RhoGDIa enhances ERa, ERb, glucocorticoid receptor and androgen receptor (AR), but not SRF or Sp1, mediated transactivation in transient transfection assays. A subsequent study by this group suggested that RhoGDIa enhances ERamediated transactivation indirectly through its effects on ERa-associated coregulatory proteins (Su et al. 2002) . In contrast to these studies which proposed that the cytoplasmic RhoGDIa is responsible for altering estrogen-responsive gene expression, our studies provide evidence that nuclear RhoGDIa, through its interaction with ERa, also plays a direct role in regulating ERa-mediated transactivation. The presence of RhoGDIa in MCF-7 nuclear extracts, the localization of endogenously expressed RhoGDIa in the nucleus of MCF-7 cells, the coimmunoprecipitation of endogenously expressed RhoGDIa and ERa, and the direct interaction of purified ERa and RhoGDIa all support the idea that, in addition to its cytoplasmic activity, nuclear RhoGDIa influences ERa transactivation directly by interacting with the receptor.
As indicated in our siRNA assays (Fig. 5) , RhoGDIa differentially modulates the expression of the PR and pS2 genes, which have very different cis elements and trans-acting factors involved in conferring their hormone responsiveness. While the pS2 gene contains an imperfect ERE that interacts directly with ERa (Nunez et al. 1989) , the PR gene contains multiple AP-1 and Sp1 sites through which AP-1 and Sp1 proteins interact with ERa (Jeltsch et al. 1987 , Petz et al. 2002 , 2004a ,b, Schultz et al. 2003 . Thus, we believe that the ability of RhoGDIa to differentially alter estrogen-responsive gene expression may be due to differences in the population of cis elements and the trans-acting factors associated with various target genes.
As might be expected from the effects of RhoGDIa on estrogen-responsive gene expression, this protein is required for fertility and reproductive competence in mice. RhoGDIaK/K males have spermatogenesis defects and are infertile and RhoGDIaK/K females have implantation defects (Togawa et al. 1999) . Thus, RhoGDIa not only influences estrogen-responsive gene expression in MCF-7 breast cancer cells, but also has profound effects on the reproductive tract and reproduction.
Interestingly, there is evidence for the involvement of other GTPase regulatory proteins in influencing nuclear receptor activity. For example, the GEF protein Brx interacts directly with and enhances the transcriptional activity of ERa (Rubino et al. 1998 ) and the glucocorticoid receptor (Kino et al. 2006 ). Vav3, another GEF protein, increases AR-mediated transactivation, but does not appear to interact with the receptor (Lyons & Burnstein 2006) . It is thought that the ability of Vav3 to enhance AR responsiveness may contribute to the relapse of prostate cancer in patients undergoing androgen deprivation therapy (Lyons & Burnstein 2006) . Interestingly, RhoGDIa, which opposes the actions of GEFs on RhoGTPases, increases the resistance of cancer cells to chemotherapeutic agents (Zhang et al. 2005) . The ability of RhoGDIa to act as a nuclear receptor coregulatory protein challenges the classical paradigm in which this protein is solely involved in the propagation of signals initiated at the plasma membrane. Our studies suggest that the nuclear actions of RhoGDIa supplement its effects in the cytoplasm and that RhoGDIa functions in both membrane and nuclear signaling pathways.
